Publications

5429 Results

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Authors
G Garcia-Manero;N Podoltsev;M Othus;J Pagel;J Radich;M Fang;D Rizzieri;G Marcucci;SA Strickland;MR Litzow;M Savoie;B Medeiros;M Sekeres;TL Lin;G Uy;BL Powell;JE Kolitz;RA Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;F Appelbaum;HP Erba
Journal / Conference
Leukemia Jan;38(1):58-66
Year
2024
Research Committee(s)
Leukemia
PMID
PMID37935977
Study Number(s)
S1203

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Authors
S Lerner;D McConkey;C Tangen;JJ Meeks;T Flaig;X Hua;S Daneshmand;A Alva;MS Lucia;D Theodorescu;A Goldkorn;M Milowsky;W Choi;R Bangs;D Gustafson;M Plets;IM Thompson
Journal / Conference
Clinical Cancer Research Jan 17;30(2):444-449
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID37966367
PMC
PMC10824507
Study Number(s)
S1314

A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia

Authors
S Patel;M Othus;Y Chae;M Dennis;S Gordon;D Mutch;W Samlowski;W Robinson;E Sharon;C Ryan;G Lopez;M Plets;C Blanke;R Kurzrock
Journal / Conference
Clinical Cancer Research Jan 5;30(1):33-38
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID37882676
PMC
PMC10842092
Study Number(s)
S1609

Predicting clinical outcomes in the S1314-COXEN Trial using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression

Authors
B Faltas;Z Bai;M Osman;M Brendel;C Tangen;T Flaig;M Plets;MS Lucia;D Theodorescu;D Gustafson;S Daneshmand;J Meeks;W Choi;C Dinney;O Elemento;S Lerner;D McConkey;F Wang
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1314

PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)

Authors
B Maughan;M Plets;Y Ged;C Tangen;U Vaishampayan;S Lerner;S Lerner;I Thompson
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S2200

SWOG S2210: A PHASE II STUDY OF NEOADJUVANT CARBOPLATIN FOR LOCALIZED, HIGH RISK PROSTATE CANCER WITH GERMLINE BRCA1/2 MUTATIONS

Authors
H Cheng;S Callis;D Lin;E Yu;T Dorff;A Kase;C Tangen;D Petrylak;S Lerner
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S2210

AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIBC) vs Observation

Authors
A Apolo;K Ballman;G Sonpavde;S Berg;W Kim;R Parikh;M Teo;R Sweis;D Geynisman;P Grivas;E Levine;Z Reichert;J Kim;M Bilen;Y Wen;O Hahn;S Halabi;G Perez;M Morris;J Rosenberg
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/A031501

Bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient level analysis of SWOG 1216 trial

Authors
G Gebrael;M Plets;Y Jo;U Swami;C Chehade;A Narang;S Gupta;N Sayegh;C Tangen;M Hussain;T Dorff;P Lara;S Lerner;I Thompson;N Agarwal
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Urinary comprehensive genomic profile correlates with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605

Authors
M St-Laurent;M Plets;P Black;P Singh;D McConkey;MS Lucia;V Koshkin;K Stratton;T Bivalacqua;W Kassouf;S Porten;R Bangs;C Tangen;I Thompson;J Meeks;V Caruso;K Philllips;V Bicocca;T Levin;S Lerner
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1605

Correlation Between Tumor Size Change and Outcome in a Rare Cancer Immunotherapy Basket Trial

Authors
M Othus;S Patel;YK Chae;H Streicher;E Sharon;R Kurzrock
Journal / Conference
Journal of the National Cancer Institute Jan 18:djae009. doi: 10.1093/jnci/djae009. Online ahead of print
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID38243705
Study Number(s)
S1609